טוען...
Targeting resistance to targeted therapies: combating a resilient foe
While the advent of third generation therapies have dramatically changed the treatment paradigm for EGFR mutated lung cancer, resistance to these agents inevitably emerges. Understanding resistance mechanisms and their genomic underpinnings is crucial for developing innovative strategies that are ca...
שמור ב:
| הוצא לאור ב: | Clin Cancer Res |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6295273/ https://ncbi.nlm.nih.gov/pubmed/30352903 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-3178 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|